Matthews, D. R. Et Al. 2019. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. LANCET , vol.394, no.10208 , 1519-1529.

Matthews, D. R., Paldanius, P. M., Proot, P., Chiang, Y., Stumvoll, M., & Del Prato, S., (2019). Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. LANCET , vol.394, no.10208, 1519-1529.

Matthews, Hasan Et Al. "Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial," LANCET , vol.394, no.10208, 1519-1529, 2019

Matthews, Hasan Et Al. "Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial." LANCET , vol.394, no.10208, pp.1519-1529, 2019

Matthews, D. R. Et Al. (2019) . "Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial." LANCET , vol.394, no.10208, pp.1519-1529.

@article{article, author={Hasan KUDAT Et Al. }, title={Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial}, journal={LANCET}, year=2019, pages={1519-1529} }